Literature DB >> 1157430

Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.

O R Hommes, J J Prick, K J Lamers.   

Abstract

32 patients with the chronic progressive form of the multiple sclerosis were treated with high doses of cyclophosphamide and prednisone during 20 days, to produce immunosuppression. The effect of treatment was measured by scoring three different Kurtzke scales just before treatment (1), just after treatment (II), and 3 months after treatment (III). The results indicate that in the treatment period I to II most patients improve, some dramatically. The improvement continues in 15 of 25 patients scored between 6 and 33 months after treatment. Better results were found in patients with shorter duration of their disease. More improvement is found as the IgG percentage of the spinal fluid at I is higher. The improvement is less when the initial condition (I) is more serious.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157430     DOI: 10.1016/s0303-8467(75)80007-2

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  14 in total

1.  Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study.

Authors:  L La Mantia; M Eoli; A Salmaggi; V Torri; C Milanese
Journal:  Ital J Neurol Sci       Date:  1998-02

2.  Cyclophosphamide treatment in active multiple sclerosis.

Authors:  Enrique Gómez-Figueroa; Efrain Gutierrez-Lanz; Alonso Alvarado-Bolaños; Adriana Casallas-Vanegas; Christian Garcia-Estrada; Indhira Zabala-Angeles; Arturo Cadena-Fernandez; Rivas-Alonso Veronica; Treviño-Frenk Irene; José Flores-Rivera
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

3.  Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors:  Amer Awad; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 4.  Cyclophosphamide for multiple sclerosis.

Authors:  L La Mantia; C Milanese; N Mascoli; R D'Amico; B Weinstock-Guttman
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.

Authors:  P Theys; F Gosseye-Lissoir; P Ketelaer; H Carton
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

6.  Failure of basic protein therapy for multiple sclerosis.

Authors:  R E Gonsette; P Delmotte; L Demonty
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

7.  Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.

Authors:  W W Shih; R W Baumhefner; W W Tourtellotte; C M Haskell; E L Korn; J L Fahey
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

8.  Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Authors:  Chitra Krishnan; Adam I Kaplin; Robert A Brodsky; Daniel B Drachman; Richard J Jones; Dzung L Pham; Nancy D Richert; Carlos A Pardo; David M Yousem; Edward Hammond; Megan Quigg; Carrilin Trecker; Justin C McArthur; Avindra Nath; Benjamin M Greenberg; Peter A Calabresi; Douglas A Kerr
Journal:  Arch Neurol       Date:  2008-06-09

9.  Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness.

Authors:  U Patzold; P Pocklington
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

10.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.